Please assess the completion status of the following clinical trial:

Trial Title: Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provided signed, written informed consent~* At least 18 years of age~* Had a diagnosis of AML according to World Health Organization (WHO) classification~* First relapsed or refractory AML (refractory to initial induction therapy) with at least 5% blasts by bone marrow or aspirate or 1% blasts in peripheral blood with additional requirements for relapsed or refractory~* Had an ECOG score of 0-2~* Had adequate liver and renal function as indicated by certain laboratory values~* Had adequate cardiac function (left ventricular ejection fraction at least 40% by multiple gated acquisition scan or ECG)~* Nonfertile or agreed to use an adequate method of contraception until 30 days after the last treatment~* Had any clinically significant nonhematologic toxicity after prior chemotherapy recovered to Grade 1 per NCI-CTCAE~Exclusion Criteria:~* Had acute promyelocytic leukemia~* Had more than 2 cycles of induction therapy for AML~* Had completed a single cycle of treatment containing a total dose of 5 g/m2 or more of cytarabine within 90 days before randomization~* Refractory to or relapsed within the previous 3 months after therapy with an IDAC- or HIDAC-containing regimen~* Had received a hematopoietic stem cell transplant (HSCT) within the previous 90 days~* Had received active immunosuppressive therapy for graft-versus-host disease (GVHD) within 2 weeks before study start~* Had any other severe concurrent disease, or have a history of serious disease involving the heart, kidney, liver, or other organ system~* Had evidence of central nervous system involvement of active AML~* Had other active malignancies (including other hematologic malignancies) or been diagnosed with other malignancies within the last 12 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia~* Had an active, uncontrolled infection~* Had received any other investigational therapy within 14 days or not recovered from acute affects of the other investigational therapy~* Had received prior or current hydroxyurea or medications to reduce blast count within 24 hours before randomization~* Had received previous treatment with vosaroxin~* Pregnant or lactating~* Had any other medical, psychological, or social condition that may interfere with consent, study participation, or follow-up~* Had known HIV seropositivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: vosaroxin + cytarabine (Type: EXPERIMENTAL): vosaroxin (short IV infusion within 10 minutes) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
- Group B: placebo + cytarabine (Type: PLACEBO_COMPARATOR): placebo (short IV infusion within 10 minutes and volume matched to vosaroxin) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation

Based on this trial design, predict the completion outcome and termination type (if applicable).